Dummer R, Hauschild A, Santinami M, et al. - Given that significantly longer relapse-free survival with 12 months of adjuvant dabrafenib plus trametinib vs placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations has been reported in the previously reported primary analysis of this phase 3 trial, so, researchers intended to generate longer-term data in order to corroborate the stability of the relapse-free survival advantage. Here, they present 5-year outcomes for relapse-free survival as well as survival without distant metastasis as the site of the first relapse. A longer duration of survival without relapse or distant metastasis was achieved with 12 months of adjuvant therapy with dabrafenib plus trametinib, vs placebo, along with no apparent long-term toxic impacts, as shown by the findings of the 5-year follow-up of a phase 3 trial including patients who had resected stage III melanoma with BRAF V600E or V600K mutations.